ARK Stock Commentary: BNTX, PSNL, PAYP

[!warning] Conflict of Interest ARK Invest is an active fund manager. These are stocks in ARK's own portfolios -- they are explaining moves in positions they hold. Read as promotional context, not independent analysis.

Movers (Week of Mar 9-13, 2026)

• BNTX (-17%): BioNTech CEO/co-founder and CMO/co-founder departing by year-end to start new mRNA company. Guided to ~25% y/y revenue decline in 2026 on lower COVID vaccine revenue.
• PSNL (-17%): Personalis (precision oncology assays) dropped in broader clinical diagnostics sector sell-off. No company-specific news.
• PAYP (+17%): PayPay Corporation (SoftBank-backed Japanese financial super-app) surged on Nasdaq IPO. QR-code mobile wallet with banking, credit cards, securities, insurance. Valued at $12.7B.

RDCO Relevance

PayPay IPO is a signal for Japanese fintech adoption and super-app model viability. BioNTech leadership departure worth monitoring for mRNA innovation landscape.